Alnuctamab 是一种靶向 BCMA 和 CD3 的双特异性 T 细胞接合器，属于不对称双臂人源化 IgG1 抗体。Alnuctamab 可同时结合表达于骨髓瘤细胞表面的 BCMA 和 T 细胞表面的 CD3 分子，招募 T 细胞杀伤肿瘤。Alnuctamab 可用于多发性骨髓瘤的研究。推荐同型对照: Human IgG1 kappa, Isotype Control。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Alnuctamab) is 192.13 kDa.

Anti-BCMA & CD3 Reference Antibody (Alnuctamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-BCMA & CD3 Reference Antibody (Alnuctamab) is 100.00%, determined by SEC-HPLC.

Alnuctamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Alnuctamab bound to huBCMA-ECD-His , and the EC50 was 0.042 nM.

Alnuctamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Alnuctamab bound to huBCMA-HEK293 cells, and the EC50 was 0.693 nM.

Alnuctamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Alnuctamab bound to huCD3e-jurkat cells, and the EC50 was 66.190 nM.

Co-incubation of Alnuctamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Alnuctamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.110 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.